Adherence influencing factors in patients taking oral anticancer agents: A systematic review
Introduction
The use of oral anticancer agents (OACA) has increased steadily. One quarter of newly developed anticancer agents can be taken orally [1]. The use of OACA will probably increase further. Most patients prefer to take their medication orally [2]. Adherence, defined as “the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen” [3] is lower in patients taking OACA compared to patients treated with intravenous chemotherapy [4]. It is estimated that adherence rates in patients taking OACA lie in a range between less than 20% and 100%, depending on patient characteristics, therapy and adherence measurement and definition [5], [6]. For some cancer types adherence to OACA turns out to be crucial factor for the success of treatment [7], [8], [9], especially given the long period in which OACA have to be taken correctly. Consequently, adherence has become a key issue in modern oncology treatment. There are several factors that can potentially influence patient adherence [10]. In clinical practice the knowledge about factors that influence patient adherence can help to identify patients at risk for non-adherence and also help to develop methods to improve adherence in affected populations.
The objective of this systematic review was to identify adherence influencing factors in patients taking OACA.
Section snippets
Sources
This systematic review was prepared according to the standards of the Cochrane collaboration, recommendations for systematic reviews of prognostic factors, and reported according MOOSE [11], [12], [13].
A systematic literature search was performed in MEDLINE (via Pubmed) and Embase (via Embase). The search strategy comprised several terms and medical subject headings related to adherence and OACA (the full search strategies are available in Supplement I). The search was performed in December
Literature search
After deducing duplicates the search in electronic databases resulted in 2309 hits. After title and abstract screening 95 seemed potentially relevant and full-text versions were screened in detail. Finally 23 publications of 22 studies were included [7], [8], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37]. The manual search and reference-check revealed no further relevant publications. The flowchart illustrates the
Discussion
Age, ethnic status, social support, depression, intake of aromatase inhibitors, number of different medications, and out-of-pocket costs seem to have an effect on adherence. The remaining factors either showed mostly no influence or a clear conclusion is not possible, because the results differed between studies. Due to the heterogeneity no general conclusions for all factors, – also for those emphasized above can be made that can be applied to all indications, medications, settings, countries
Conflict of interest
This work was funded by Janssen-Cilag Germany. There is no other conflict of interest.
Funding
This work was funded by Janssen-Cilag Germany. The sponsor has no influence on the study design, and in the collection, analysis and interpretation of data. Janssen-Cilag Germany has reviewed the manuscript and provided comments. The final decision to include the comments and the decision to submit the manuscript for publication was made only by the authors.
Authorship
All authors have made substantial contributions and approved the conceptions, drafting, and final version of the manuscript.
References (45)
- et al.
Anticancer oral therapy: emerging related issues
Cancer Treat Rev
(2010) - et al.
Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
Ann Oncol
(2006) - et al.
Medication compliance and persistence: terminology and definitions
Value Health
(2008) A review on adherence management in patients on oral cancer therapies
Eur J Oncol Nurs
(2012)- et al.
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Blood
(2009) - et al.
Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper
Int J Nurs Stud
(2007) - et al.
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
Eur J Cancer
(2006) - et al.
Adherence beliefs among breast cancer patients taking tamoxifen
Patient Educ Couns
(2005) - et al.
Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?
Eur J Cancer
(2012) - et al.
Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
Leuk Res
(2009)
Does fasting during Ramadan trigger non-adherence to oral hormonal therapy in breast cancer patients?
J Egypt Natl Canc Inst
Prevalence and risk factors of non-adherence with immunosuppressive medication in kidney transplant patients
Am J Transplant
Language bias in randomised controlled trials published in English and German
Lancet
Patient adherence to oral anticancer drugs: an emerging issue in modern oncology
Acta Clin Belg
Adherence to therapy with oral antineoplastic agents
J Natl Cancer Inst
Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer
Breast Cancer Res Treat
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
Breast Cancer Res Treat
Adherence to long-term therapies: evidence for action
Cochrane handbook for systematic reviews of interventions version 5.1.0
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group
JAMA
Systematic reviews of low back pain prognosis had variable methods and results: guidance for future prognosis reviews
J Clin Epidemiol
The guidelines manual
Cited by (0)
- 1
Tel.: +49 0221 98957 42; fax: +49 0221 98957 30.
- 2
Tel.: +49 0221 98957 49; fax: +49 0221 98957 30.
- 3
Tel.: +49 0221 98957 40; fax: +49 0221 98957 30.